The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis

Circulation

Volumn 93, Issue 1, 1996, Pages 129-134

  Frederick, Leo G ^a   Suleymanov, Osman D ^a   King, Lucy W ^a   Salyers, Anita K ^a   Nicholson, Nancy S ^a   Feigen, Larry P ^a  

^a PFIZER INC   (United States)

Author keywords

aggregation; antithrombotic agents; platelets; thrombosis

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; XEMILOFIBAN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFECT; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0030027872     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.1.129     Document Type: Article

References (37)

1. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981; 304:685-691.
2. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
3. Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol. 1986;8:245-250.
4. Rubenstein MD, Wall RT, Baim DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J. 1981;102:363-367.
5. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol. 1981;48:395-402.
6. Fuster V, Steele PM, Chesebro JH. Role of platelet and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 1985;5:175B-184B.
7. Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J. 1977;93: 468-486.
8. Vetrovec GW, Crowley MJ, Overton H, Richardson DW. Intracoronary thrombus in syndromes of unstable myocardial ischemia: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Am Heart J. 1981;102:1202-1208.
9. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation. 1985;71:699-708.
10. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
11. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature. 1971;231:235-237.
12. Thebault JJ, Blatri CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor, in man. Clin Pharmacol Ther. 1975;18:485-491.
13. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla-Volta S. Adenosine diphosphate (ADP)-induced alpha-granule release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost. 1986;56:147-150.
14. 2 and serotonin after thrombolysis with tPA in a canine preparation of coronary thrombosis. Circulation. 1988;77:678-684.
15. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393-1401.
16. Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980;55:841-847.
17. Schumacher WA, Lee EC, Lucchesi BR. Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol. 1985;7:739-746.
18. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA, Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman VW, Herin M, Jacqmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation. 1995;91: 403-410.
19. 2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation. 1990;81:617-627.
20. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation. 1990;82:169-177.
21. Tschopp JF, Driscoll EM, Mu D-X, Black SC, Pierschbacher MD, Lucchesi BR. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time. Coron Artery Dis. 1993;4:809-817.
22. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976;54:365-370.
23. Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984;69:1161-1170.
24. 2 and serotonin are possible mediators. Circulation. 1989;79:154-166.
25. 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 1984;55:642-652.
26. Salyers AK, Szalony JA, Taite BB, Haas NF, Mehrotra DV, Feigen LP, Nicholson NS. A new method for measurement of plasma concentration of orally active glycoprotein IIb/IIIa anlagonists. Thromb Res. 1994;75:409-417.
27. Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction: a randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. Circulation. 1988;78:546-556.
28. Theroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, de Guise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
29. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979;254:5357-5363.
30. Travis J. Biotech gets a grip on cell adhesion: frontier in biotechnology. Science. 1993;260:906-908.
31. Feigen LP, Nicholson NS, King LW, Campion JG, Tjoeng FS, Panzer-Knodle SG. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 1993;267:1191-1197.
32. Collen D, Lu RH, Stassen J-M, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 1994;71:95-102.
33. Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, De Grado WF, Thoolen MJ, Reilly TM. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994;89:3-12.
34. Szalony JA, Haas NF, Salyers AK, Taite BB, Mehrotra DV, Feigen LP, Nicholson NS. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation. 1995;91: 403-410.
35. Freed MI, Boike S, Zariffa N, Jorkasky DK. Effects of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist. Thromb Haemost. 1994;72:622-626.
36. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol. 1993;21: 502-510.
37. Folts JD, Gallagher K, Rowe GG. Blood flow reduction in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation. 1982;65:248-255.